Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Exclusion Criteria

• •Known hypersensitivity to any of the study drugs
• •History of other malignancy that could affect compliance with the protocol or interpretation of results (Patients with a history of curatively treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix, breast cancer, or Hodgkin's Lymphoma are generally eligible. Patients with a malignancy that has been treated, but not with curative intent, will be excluded, unless the malignancy has been in remission without treatment for ≥ 2 years prior to enrollment.)
• •Evidence of other clinically significant uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal)
• •Patients on renal replacement therapy
• •Known GI disease or GI procedure that could interfere with oral absorption (including difficulty swallowing)
• •New York Heart Association (NYHA) Class III or IV heart failure
• •Mayo stage three-B (IIIB) with N-terminal pro-hormone B-type natriuretic peptide (NT-Pro BNP) \> 8500 pg/mL
• •Prior exposure to anti-apoptotic protein B-cell lymphoma 2 (BCL-2) inhibitors
• •Patients with human immunodeficiency virus (HIV) who are not on highly active antiretroviral therapy (HAART) or those with active hepatitis A, B, or C infection
• •Patients meeting criteria for symptomatic multiple myeloma by one of the following:(a) Lytic lesions on imaging (b) Plasmacytoma, (c) Hypercalcemia without any alternate etiology, or (c) Bone marrow plasma cell infiltrate of greater than 60%